BrainsWay (NASDAQ:BWAY) Posts Quarterly Earnings Results, Beats Estimates By $0.03 EPS

BrainsWay (NASDAQ:BWAY) issued its quarterly earnings data on Tuesday. The company reported $0.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.01 by $0.03, Zacks reports. The business had revenue of $10.50 million during the quarter, compared to analyst estimates of $10.07 million. BrainsWay had a return on equity of 3.56% and a net margin of 3.88%. During the same period in the previous year, the firm earned ($0.01) EPS. BrainsWay updated its FY 2024 guidance to EPS.

BrainsWay Price Performance

BWAY stock traded down $0.70 during midday trading on Wednesday, hitting $9.00. The stock had a trading volume of 162,746 shares, compared to its average volume of 95,673. The firm has a market cap of $150.12 million, a PE ratio of 91.01 and a beta of 1.25. BrainsWay has a 12-month low of $3.80 and a 12-month high of $10.98. The company’s 50-day moving average price is $9.11 and its 200 day moving average price is $7.40.

Analysts Set New Price Targets

A number of brokerages have weighed in on BWAY. Northland Securities increased their price objective on BrainsWay from $11.00 to $12.50 and gave the company an “outperform” rating in a report on Thursday, October 3rd. HC Wainwright reissued a “buy” rating and issued a $16.00 target price on shares of BrainsWay in a research report on Monday, October 21st.

About BrainsWay

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.